Eplerenone in patients with systolic heart failure and mild symptoms.
about
The Renin-Angiotensin-aldosterone system in vascular inflammation and remodelingESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryDigitalis for treatment of heart failure in patients in sinus rhythmDigitalis for treatment of heart failure in patients in sinus rhythmDevices in the management of advanced, chronic heart failureCritical Questions about PARADIGM-HF and the FutureMineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectivesHeart Failure: Diagnosis, Management and UtilizationImpact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsNovel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of CardiologyRecent advances in treatment of heart failureNew Insights in the Diagnosis and Treatment of Heart FailureReview of the top 5 cardiology studies of 2013-14Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic ReviewAtrial fibrillation in heart failure: what should we do?Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?"Management of Patients Admitted with Acute Decompensated Heart FailureSafety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial dataEffects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-AnalysisThe autocrine/paracrine loop after myocardial stretch: mineralocorticoid receptor activationThe ubiquitous mineralocorticoid receptor: clinical implicationsBrain mineralocorticoid receptors in cognition and cardiovascular homeostasisCongestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvementPharmacology of Aldosterone and the Effects of Mineralocorticoid Receptor Blockade on Cardiovascular SystemsThe kidney in congestive heart failure: 'are natriuresis, sodium, and diuretics really the good, the bad and the ugly?'The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitorsAldosterone synthase inhibition in humansIs there a new dawn for selective mineralocorticoid receptor antagonism?Heart Failure: a Major Cardiovascular Complication of Diabetes MellitusGetting to the heart of intracellular glucocorticoid regeneration: 11β-HSD1 in the myocardiumA Review of the Key Clinical Trials of 2015: Results and ImplicationsPresent and future pharmacotherapeutic agents in heart failure: an evolving paradigm2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of theA reappraisal of loop diuretic choice in heart failure patientsDiuretics: a review and updateLong-term use of secondary prevention medications for heart failure in Western Australia: a protocol for a population-based cohort studyGlobal Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials.Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-AnalysisPotential new drug treatments for congestive heart failure.Evaluation of Short-Term Changes in Serum Creatinine Level as a Meaningful End Point in Randomized Clinical Trials.
P2860
Q21284671-CD2DBBFE-49B1-48D8-8BAA-B709F9D6CFF9Q22241786-4F69307A-74CE-4B93-BD65-DE529D5F991AQ24194992-77F28BB4-D8C7-40D6-B692-804D77226696Q24247158-2C437072-55AD-4D20-8698-5CC59C9D89AAQ24630052-06EF1C13-341E-4F7F-AF17-E87620EDE8A1Q26741029-C3F1A842-85F8-464D-80F6-44ADCD2F9908Q26741152-106B0160-7913-4FC3-B388-FA5755DD3F55Q26745543-6EDB5B06-D2C1-4C80-B3A6-C3AF8ABB246DQ26764927-478EBA9F-5026-4EF6-B591-5605BE848DE0Q26765793-1712CB16-F3D4-4F46-ABC7-2CB44113F46FQ26766223-F37F76DB-33FF-4E3D-A213-62808B2357BDQ26774884-1DBB2636-EDC0-453A-AFD5-56DC866C0382Q26776254-DFD6CE43-A798-48E9-8005-6E26C2B4A653Q26783958-00F61F4C-D793-4D4E-BBC9-82E75F5BACA9Q26784426-65635395-7135-43F2-A3CC-8D22D55B16D0Q26785931-1E9A80F4-738A-417F-B20C-AE74179F15A2Q26786085-98A0EC39-9D81-4116-9942-EA8131ED43DCQ26796271-9699FC0D-D486-43E5-B6C4-52F18E9C0B58Q26801321-46A7F2B3-BC4B-4289-ACD8-CB929617C7FEQ26826836-EAD48301-075A-4C6D-9CB2-2405A2C0E823Q26861721-87478A96-3214-46A6-836C-5710A72801F1Q26995642-63DB2EFC-355E-447A-BDBE-C148621158D3Q27003819-EFA8994E-C509-40C4-90E0-323E4367B3F3Q27010641-B5764FE9-D05C-49F8-8AD6-EC49ABD2D8E1Q27011043-BF82B773-8FEA-489D-9230-2BF962B4FFACQ27011540-B095432D-3E10-493F-8DD9-71420E45F76AQ27016157-94A93EEA-F2BF-4101-A690-E0A942F57AEBQ27027792-4F688D66-0910-4965-873E-505663D5161CQ28066310-78A4138D-6718-46F8-9A3D-1CFB77D7AEF9Q28067162-D2429345-F97B-45DF-BF1C-CEA437C11D8EQ28077170-B1DDA703-C2EB-44E1-B9DC-DA4A17DD8D61Q28077186-674AC1FB-492B-4B13-BF40-644196118FA1Q28087002-223D52EE-485E-4669-BA3B-25EC30BDFFA8Q28258044-9EC57D40-6D01-4095-8F30-86F02D23D7FCQ28302157-D5F4CF9F-C00C-4906-BAC8-5CE0791E6713Q28591667-E2056868-2F4E-4A20-A16C-C939AE50ABD9Q30235985-DB81AFA0-DD19-4586-8F81-D16A52EAB8B9Q30239022-D08D69A7-F60F-4A04-8D59-318556BB1550Q30251531-52AF8B5D-4C64-4B4A-91AA-BCF70B3874DEQ30251988-0C55D01D-CCE2-40D9-A084-FFA7E26B2D7F
P2860
Eplerenone in patients with systolic heart failure and mild symptoms.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Eplerenone in patients with systolic heart failure and mild symptoms.
@en
Eplerenone in patients with systolic heart failure and mild symptoms.
@nl
type
label
Eplerenone in patients with systolic heart failure and mild symptoms.
@en
Eplerenone in patients with systolic heart failure and mild symptoms.
@nl
prefLabel
Eplerenone in patients with systolic heart failure and mild symptoms.
@en
Eplerenone in patients with systolic heart failure and mild symptoms.
@nl
P2093
P50
P921
P356
P1476
Eplerenone in patients with systolic heart failure and mild symptoms.
@en
P2093
EMPHASIS-HF Study Group
John J V McMurray
John Vincent
Stuart J Pocock
P356
10.1056/NEJMOA1009492
P407
P577
2010-11-14T00:00:00Z